Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.46 |
| ▸ | CTRC | Q99895 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8309719 | 0.86 | ELANE (0.46) | ELANECTRCCASP1 | |
| SCHEMBL8312981 | 0.78 | ELANE (0.55) | ELANECTRCNPC1RAB9A | |
| SCHEMBL4461122 | 0.75 | PSMB1 (0.64) | BACE1PSMB1 | |
| SCHEMBL23835788 | 0.74 | NPC1 (0.58) | ELANECTRCNPC1RAB9A | |
| SCHEMBL952097 | 0.72 | NPC1 (0.55) | ELANECTRCNPC1RAB9ACASP1 | |
| SCHEMBL1039440 | 0.71 | NPC1 (0.54) | ELANECTRCNPC1RAB9ACASP1 | |
| SCHEMBL1039441 | 0.71 | NPC1 (0.54) | ELANECTRCNPC1RAB9ACASP1 | |
| SCHEMBL4491942 | 0.69 | CTSD (0.52) | ELANECASP1 | |
| SCHEMBL12273254 | 0.68 | NPC1 (0.53) | ELANENPC1RAB9ACASP1 | |
| SCHEMBL4902533 | 0.68 | NPC1 (0.53) | ELANENPC1RAB9ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504382-B2 | Protease inhibitors for coronaviruses and SARS-CoV and the use thereof | CYTOVIA, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC. | 2008-12-04 | — | — | US | disclosed |
| WO-2004101742-A2 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | CYTOVIA, INC (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300191-A1 | PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF | ACE, ACE2, TMPRSS2 | ELANE 242/4885CTRC 165/4885NPC1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.